To evaluate the oncological outcomes of Robotic-Assisted Thoracic Surgery (RATS) versus Video-Assisted Thoracic Surgery (VATS) for early-stage lung cancer.
Approach:
Oncologic outcomes: Numerous studies indicate comparable outcomes between RATS and VATS, with recent trials confirming non-inferiority in perioperative outcomes and oncological efficacy.
Lymphadenectomy: Surgeon skill and determination in performing radical lymph node dissection are critical for survival, with RATS showing higher nodal upstaging rates in some studies.
Learning curve: The learning curve for RATS is influenced by prior VATS experience, with robotic platforms potentially facilitating better surgical outcomes.
Cost effectiveness: RATS incurs higher costs and longer operating times compared to VATS, raising concerns about its cost-effectiveness in healthcare.
Tailored surgical strategy: A tailored approach is advocated, allowing surgeons to choose the method based on case complexity and their proficiency.
Key Findings:
RATS and VATS show comparable oncological outcomes.
Surgeon skill is a significant factor in achieving successful lymphadenectomy.
RATS may lower the technical barrier for complex procedures but does not guarantee superior outcomes for all surgeons.
RATS is associated with higher costs and longer operating times without improved adverse event rates.
Interpretation:
The choice between RATS and VATS should be based on the surgeon's expertise and the specific case rather than a strict preference for one technology over the other.
Limitations:
Current evidence does not definitively prove that RATS standardizes surgical excellence.
Higher costs of RATS may limit its accessibility and adoption.
Conclusion:
Surgeons should utilize a tailored surgical strategy that leverages their strengths and the specific needs of the patient, rather than adhering strictly to one surgical platform.
